OVX836 shown to be safe and effective alongside seasonal Fluarix Tetra

BX004 achieves 500-fold bacterial reduction with no resistance in phase 1b/2a study

Funding to support lead candidate targeting FAP and pipeline expansion

New trial to test VMX-C001’s effectiveness in restoring coagulation in FXa DOAC patients

Enter the 2025 PharmaTimes Clinical Researcher of the Year – The Americas

PulseSight begins phase 1 safety study of gene therapy for geographic atrophy

SMC approval provides option for postmenopausal women at risk of fractures

CSL Behring marks new era in treatment with milestone reimbursement model

Pneumagen’s intranasal antiviral demonstrates reduced infection

Data shows mRNA-1010 could better protect adults aged 50 and above